Sarepta surges after Pfizer gene therapy data raises safety concerns
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
Go back to Sarepta surges after Pfizer gene therapy data raises safety concerns
July 1, 2019 8:04 AM EDT
Pfizer Inc. (NYSE: PFE) today announced top-line results from a Phase 4 study (CrisADe CARE 1) which showed that crisaborole ointment, 2%, was well-tolerated in children aged 3 months to less than 24 months with mild to moderate atopic dermatitis (AD), also known as eczema. The data from the trial are supportive of the primary study objective to examine the safety of crisaborole ointment, 2%, in this patient population, and are consistent with previous clinical trial experience.1 Crisaborole ointment, 2%, is currently approved in select countries for mild to moderate AD in patients two years of age and older.2,3,4,5
This... More
July 1, 2019 6:18 AM EDT
RBC Capital analyst Brian Abrahams raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $220.00 (from $188.00) while maintaining an Outperform rating following DMD results from Pfizer.
Abrahams commented, "Based on our analysis of PFE's initial DMD gene therapy results - incorporating... More
